Barcelona biotech funding to tackle leading cause of inherited intellectual disability
Connecta Therapeutics has raised $3.5 million to accelerate treatment for Fragile X syndrome, with trial results expected mid-2027.
The clinical-stage biotechnology company, which specializes in developing neuroplasticity modulators for central nervous system (CNS) disorders, will use the capital to advance its ongoing Phase IIa (NCT07654114) clinical trial of CTH120. CTH120 is the company's lead drug candidate for adult males living with Fragile X syndrome.
The financing round was led by new investor Clave Capital through its Innvierte Science Tech Clave Innohealth fund, with continued support from existing investors including Inveready, CDTI Innvierte, and Prous Institute for Biomedical Research.
“The funding round was primarily focused on completing our Phase IIa clinical trial in Fragile X syndrome patients, while also positioning the company for the forthcoming investment to advance the FRAXCURE project supported by the EIC Accelerator program,” Josep Prous Jr, co-founder and CSO of Connecta, told BioXconomy.
“This approach allows us to generate important clinical data and reach a key develo...